Silverarc Capital Management, LLC 13F holdings, Q3 2024
Holdings as of September 30, 2024 · filings on SEC EDGAR · latest filing →
Silverarc Capital Management, LLC disclosed 68 US equity positions worth $443.8m in its Q3 2024 13F filing. The largest position was NUVALENT INC at 8.6% of the reported book, followed by MERUS N V and INSM.
What did Silverarc Capital Management, LLC own in Q3 2024? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | NUVALENT INC | 8.6% | $38.0m | 371,441 | – | ||
| 2 | MERUS N V | 7.2% | $31.7m | 635,439 | – | ||
| 3 | INSM INSMED INC | Healthcare | 5.7% | $25.4m | 347,695 | – | |
| 4 | RNAGBP AVIDITY BIOSCIENCES INC | 4.9% | $21.8m | 475,555 | – | ||
| 5 | ERAS ERASCA INC | Healthcare | 4.3% | $19.0m | 6,946,488 | – | |
| 6 | AKERO THERAPEUTICS INC | 4.1% | $18.4m | 639,840 | – | ||
| 7 | VCYT VERACYTE INC | Healthcare | 3.6% | $16.0m | 470,565 | – | |
| 8 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 3.0% | $13.4m | 255,578 | – | |
| 9 | COGT COGENT BIOSCIENCES INC | Healthcare | 3.0% | $13.2m | 1,221,362 | – | |
| 10 | ITCIEUR INTRA-CELLULAR THERAPIES INC | 2.8% | $12.2m | 167,110 | – | ||
| 11 | CNTA CENTESSA PHARMACEUTICALS PLC | 2.7% | $11.9m | 744,592 | – | ||
| 12 | URGN UROGEN PHARMA LTD | Healthcare | 2.6% | $11.4m | 901,129 | – | |
| 13 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 2.5% | $11.3m | 1,099,490 | – | |
| 14 | PSTXUSD POSEIDA THERAPEUTICS INC | 2.4% | $10.5m | 3,687,548 | – | ||
| 15 | VRNA VERONA PHARMA PLC | 2.3% | $10.0m | 348,866 | – | ||
| 16 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 2.2% | $9.8m | 35,774 | – | |
| 17 | GERN GERON CORP | Healthcare | 1.8% | $8.2m | 1,801,561 | – | |
| 18 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 1.6% | $7.3m | 378,746 | – | |
| 19 | PCVX VAXCYTE INC | Healthcare | 1.6% | $6.9m | 60,500 | – | |
| 20 | 4XC1 KALVISTA PHARMACEUTICALS INC | 1.5% | $6.7m | 574,558 | – | ||
| 21 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 1.5% | $6.6m | 146,657 | – | |
| 22 | CCCC C4 THERAPEUTICS INC | Healthcare | 1.5% | $6.5m | 1,147,891 | – | |
| 23 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 1.4% | $6.4m | 51,245 | – | |
| 24 | BDSX BIODESIX INC | 1.4% | $6.3m | 3,561,094 | – | ||
| 25 | ELUT ELUTIA INC | 1.4% | $6.3m | 1,645,808 | – | ||
| 26 | ADCT ADC THERAPEUTICS SA | Healthcare | 1.3% | $5.7m | 1,795,080 | – | |
| 27 | GOSS GOSSAMER BIO INC | Healthcare | 1.3% | $5.6m | 5,645,352 | – | |
| 28 | OLMA OLEMA PHARMACEUTICALS INC | Healthcare | 1.2% | $5.4m | 455,082 | – | |
| 29 | HELIX ACQUISITION CORP II | 1.2% | $5.4m | 513,369 | – | ||
| 30 | ABVX ABIVAX SA | 1.2% | $5.3m | 461,660 | – | ||
| 31 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 1.2% | $5.1m | 627,552 | – | |
| 32 | IRON DISC MEDICINE INC | Healthcare | 1.2% | $5.1m | 103,862 | – | |
| 33 | BHVN BIOHAVEN LTD | Healthcare | 1.1% | $5.0m | 99,566 | – | |
| 34 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 1.1% | $4.9m | 145,000 | – | |
| 35 | LONGBOARD PHARMACEUTICALS IN | 0.9% | $4.1m | 124,353 | – | ||
| 36 | BIIB BIOGEN INC | Healthcare | 0.9% | $3.9m | 19,940 | – | |
| 37 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 0.9% | $3.9m | 67,045 | – | |
| 38 | MODULAR MED INC | 0.7% | $3.2m | 1,440,000 | – | ||
| 39 | SLDB SOLID BIOSCIENCES INC | Healthcare | 0.7% | $3.2m | 457,739 | – | |
| 40 | BNTX BIONTECH SE | Healthcare | 0.7% | $3.1m | 26,083 | – | |
| 41 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 0.7% | $3.1m | 70,516 | – | |
| 42 | MERSANA THERAPEUTICS INC | 0.7% | $3.0m | 1,585,786 | – | ||
| 43 | RLAY RELAY THERAPEUTICS INC | Healthcare | 0.7% | $3.0m | 419,242 | – | |
| 44 | TELA TELA BIO INC | 0.6% | $2.8m | 1,124,928 | – | ||
| 45 | CGEN COMPUGEN LTD | Healthcare | 0.6% | $2.7m | 1,501,113 | – | |
| 46 | CERS CERUS CORP | Healthcare | 0.6% | $2.6m | 1,495,329 | – | |
| 47 | ZVRA ZEVRA THERAPEUTICS INC | 0.5% | $2.4m | 350,000 | – | ||
| 48 | CATX PERSPECTIVE THERAPEUTICS INC | 0.5% | $2.2m | 167,986 | – | ||
| 49 | BIOA BIOAGE LABS INC | 0.5% | $2.1m | 100,000 | – | ||
| 50 | UNCY UNICYCIVE THERAPEUTICS INC | 0.4% | $1.6m | 4,000,000 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.